Fig. 3
From: BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer
Depletion of BCL9 changes T-cell cellular landscapes. a The workflow of scRNA sequencing. b tSNE plot of the tumor sample following treatment with vehicle or hsBCL9CT-24 (two groups), color-coded by their associated clusters. c Dot plot of the six clusters of T cells from (b). d tSNE plot of color-coded expression (gray to orange) of marker genes for the clusters from (c). e The proportion of CD8+ T and NK&T cells from 6 samples (vehicle and hsBCL9CT-24). f tSNE plot of the tumor sample that CT26 cells transduced with non-targeting (NT)-shRNA or Bcl9-shRNA (two groups), color-coded by their associated clusters. g Dot plot of the seven clusters of T cells from (f). h tSNE plot of color-coded expression (gray to orange) of marker genes for the clusters from (g). i The proportion of CD8+ T and NK&T cells from 6 samples (NT-shRNA and Bcl9-shRNA)
